1. The angiogenesis inhibitor vasostatin is regulated by neutrophil elastase–dependent cleavage of calreticulin in AML patients by Sarah Mans, Yara Banz, Beatrice U. Mueller, and Thomas Pabst Blood Volume 120(13):2690-2699 September 27, 2012 ©2012 by American Society of Hematology

2. Anthracyclin treatment induces CRT expression on the cell surface and in the serum. Sarah Mans et al. Blood 2012;120:2690-2699 ©2012 by American Society of Hematology

3. Calreticulin surface expression (cs-CRT) and extracellular serum CRT levels in patients with AML. (A) Leukemic cells from patients with AML at diagnosis and myeloid cells from 75 healthy volunteers were CD45+ gated and CD33+/CRT+ cells were determined. Sarah Mans et al. Blood 2012;120:2690-2699 ©2012 by American Society of Hematology

4. NE releases N-terminus CRT in patients with AML. (A) Recombinant full-length CRT protein was digested by NE at pH 6.0 and pH 7.4 for 2 hours. Sarah Mans et al. Blood 2012;120:2690-2699 ©2012 by American Society of Hematology

5. Vasostatin impairs differentiation. Sarah Mans et al. Blood 2012;120:2690-2699 ©2012 by American Society of Hematology

6. Vasostatin levels inversely correlate with MVD in patients with AML. Immunohistochemical staining of bone marrow biopsies with von VWF identifying endothelial vessel structures (stained brown). Sarah Mans et al. Blood 2012;120:2690-2699 ©2012 by American Society of Hematology

7. Patients with increased vasostatin levels have a favorable outcome. Sarah Mans et al. Blood 2012;120:2690-2699 ©2012 by American Society of Hematology